An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-04

AUTHORS

I Kümler, R L Eefsen, Peter Grundtvig Sørensen, S Theile, A Fullerton, P G Nielsen, Benny Vittrup Jensen, D L Nielsen

ABSTRACT

PURPOSE: Oral administration of chemotherapy offers several advantages in comparison with intravenous administration. Previously, data on a new oral formulation of irinotecan have been published. The aim of the present study was to evaluate the safety, tolerability, and Maximum Tolerated Dose (MTD) of the new oral irinotecan formulation in combination with oral capecitabine. METHODS: The study was an open label, phase 1, single center, extension part in which oral irinotecan was investigated in combination with capecitabine. The MTD of irinotecan in combination with capecitabine was 17.5 mg/m2 once daily for 14 consecutive days in combination with capecitabine 800 mg/m2 twice daily. Eligible patients were adults with metastatic or unresectable solid tumors for which no standard curative or palliative therapies existed. RESULTS: 14 patients were included in the extension part. No grade 3 or 4 hematologic toxicities were observed. Non-hematological toxicities included grade 1 and 2 diarrhea, fatigue, cholinergic syndrome, vomiting, and weight loss. Totally, 3 grade 3 toxicities and no grade 4 event were reported. No objective responses were observed. Five patients had stable disease lasting median 14 weeks. CONCLUSIONS: Capecitabine in combination with oral irinotecan could be a new treatment option offering a more convenient and patient friendly treatment strategy compared to intravenous irinotecan. The combination is fairly tolerated; however, further investigations are needed to assess the efficacy of this regimen. More... »

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-019-03819-0

DOI

http://dx.doi.org/10.1007/s00280-019-03819-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113185174

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30949758


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark. ibekml01@regionh.dk."
          ], 
          "type": "Organization"
        }, 
        "familyName": "K\u00fcmler", 
        "givenName": "I", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eefsen", 
        "givenName": "R L", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "S\u00f8rensen", 
        "givenName": "Peter Grundtvig", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Theile", 
        "givenName": "S", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Oncoral Pharma ApS, c/o Jusmedico, Kongevejen 371, Holte, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fullerton", 
        "givenName": "A", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Oncoral Pharma ApS, c/o Jusmedico, Kongevejen 371, Holte, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nielsen", 
        "givenName": "P G", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jensen", 
        "givenName": "Benny Vittrup", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nielsen", 
        "givenName": "D L", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-004-0874-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007848801", 
          "https://doi.org/10.1007/s00280-004-0874-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdl071", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008381637"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-012-9824-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010172644", 
          "https://doi.org/10.1007/s10637-012-9824-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-012-9824-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010172644", 
          "https://doi.org/10.1007/s10637-012-9824-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-14-986", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015583184", 
          "https://doi.org/10.1186/1471-2407-14-986"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e31804b40bb", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022936341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e31804b40bb", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022936341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-05-2368", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024763018"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-010-9528-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026463355", 
          "https://doi.org/10.1007/s10637-010-9528-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu260", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029291056"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds122", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033567728"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mcg.0b013e3182470f09", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037963679"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mcg.0b013e3182470f09", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037963679"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000421-198212000-00014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045278392"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000421-198212000-00014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045278392"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdv295", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045601700"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758834009355164", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064077267"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758834009355164", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064077267"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077675908", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw350", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079330788"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4143/crt.2017.562", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101054104"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4143/crt.2017.562", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101054104"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30140-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101553187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30140-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101553187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30140-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101553187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-018-3720-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109785986", 
          "https://doi.org/10.1007/s00280-018-3720-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-018-3720-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109785986", 
          "https://doi.org/10.1007/s00280-018-3720-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-018-3720-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109785986", 
          "https://doi.org/10.1007/s00280-018-3720-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-018-3720-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109785986", 
          "https://doi.org/10.1007/s00280-018-3720-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-04", 
    "datePublishedReg": "2019-04-04", 
    "description": "PURPOSE: Oral administration of chemotherapy offers several advantages in comparison with intravenous administration. Previously, data on a new oral formulation of irinotecan have been published. The aim of the present study was to evaluate the safety, tolerability, and Maximum Tolerated Dose (MTD) of the new oral irinotecan formulation in combination with oral capecitabine.\nMETHODS: The study was an open label, phase 1, single center, extension part in which oral irinotecan was investigated in combination with capecitabine. The MTD of irinotecan in combination with capecitabine was 17.5\u00a0mg/m2 once daily for 14 consecutive days in combination with capecitabine 800\u00a0mg/m2 twice daily. Eligible patients were adults with metastatic or unresectable solid tumors for which no standard curative or palliative therapies existed.\nRESULTS: 14 patients were included in the extension part. No grade 3 or 4 hematologic toxicities were observed. Non-hematological toxicities included grade 1 and 2 diarrhea, fatigue, cholinergic syndrome, vomiting, and weight loss. Totally, 3 grade 3 toxicities and no grade 4 event were reported. No objective responses were observed. Five patients had stable disease lasting median 14 weeks.\nCONCLUSIONS: Capecitabine in combination with oral irinotecan could be a new treatment option offering a more convenient and patient friendly treatment strategy compared to intravenous irinotecan. The combination is fairly tolerated; however, further investigations are needed to assess the efficacy of this regimen.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-019-03819-0", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }
    ], 
    "name": "An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine.", 
    "productId": [
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30949758"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-019-03819-0"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113185174"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-019-03819-0", 
      "https://app.dimensions.ai/details/publication/pub.1113185174"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000372_0000000372/records_117100_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s00280-019-03819-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03819-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03819-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03819-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03819-0'


 

This table displays all metadata directly associated to this object as RDF triples.

162 TRIPLES      20 PREDICATES      42 URIs      16 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-019-03819-0 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N33c97958cdcf480eaf07123cbf59cd68
4 schema:citation sg:pub.10.1007/s00280-004-0874-2
5 sg:pub.10.1007/s00280-018-3720-7
6 sg:pub.10.1007/s10637-010-9528-x
7 sg:pub.10.1007/s10637-012-9824-8
8 sg:pub.10.1186/1471-2407-14-986
9 https://app.dimensions.ai/details/publication/pub.1077675908
10 https://doi.org/10.1016/s1470-2045(18)30140-2
11 https://doi.org/10.1093/annonc/mdl071
12 https://doi.org/10.1093/annonc/mds122
13 https://doi.org/10.1093/annonc/mdu260
14 https://doi.org/10.1093/annonc/mdv295
15 https://doi.org/10.1093/annonc/mdw350
16 https://doi.org/10.1097/00000421-198212000-00014
17 https://doi.org/10.1097/coc.0b013e31804b40bb
18 https://doi.org/10.1097/mcg.0b013e3182470f09
19 https://doi.org/10.1158/1078-0432.ccr-05-2368
20 https://doi.org/10.1177/1758834009355164
21 https://doi.org/10.4143/crt.2017.562
22 schema:datePublished 2019-04-04
23 schema:datePublishedReg 2019-04-04
24 schema:description PURPOSE: Oral administration of chemotherapy offers several advantages in comparison with intravenous administration. Previously, data on a new oral formulation of irinotecan have been published. The aim of the present study was to evaluate the safety, tolerability, and Maximum Tolerated Dose (MTD) of the new oral irinotecan formulation in combination with oral capecitabine. METHODS: The study was an open label, phase 1, single center, extension part in which oral irinotecan was investigated in combination with capecitabine. The MTD of irinotecan in combination with capecitabine was 17.5 mg/m2 once daily for 14 consecutive days in combination with capecitabine 800 mg/m2 twice daily. Eligible patients were adults with metastatic or unresectable solid tumors for which no standard curative or palliative therapies existed. RESULTS: 14 patients were included in the extension part. No grade 3 or 4 hematologic toxicities were observed. Non-hematological toxicities included grade 1 and 2 diarrhea, fatigue, cholinergic syndrome, vomiting, and weight loss. Totally, 3 grade 3 toxicities and no grade 4 event were reported. No objective responses were observed. Five patients had stable disease lasting median 14 weeks. CONCLUSIONS: Capecitabine in combination with oral irinotecan could be a new treatment option offering a more convenient and patient friendly treatment strategy compared to intravenous irinotecan. The combination is fairly tolerated; however, further investigations are needed to assess the efficacy of this regimen.
25 schema:genre research_article
26 schema:inLanguage en
27 schema:isAccessibleForFree false
28 schema:isPartOf sg:journal.1088364
29 schema:name An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine.
30 schema:productId N14d8f29074224c65879be7c7111aa7b1
31 N17885ed1e35d431c8b551f2fe207e46e
32 N53f5b8c59f2d447eb989bb3a60b54bcb
33 Nab6c406afe36432d8adb82751f970cbf
34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113185174
35 https://doi.org/10.1007/s00280-019-03819-0
36 schema:sdDatePublished 2019-04-11T14:18
37 schema:sdLicense https://scigraph.springernature.com/explorer/license/
38 schema:sdPublisher N4f69ffcdc1f4460ab52d0020199cf8e0
39 schema:url http://link.springer.com/10.1007/s00280-019-03819-0
40 sgo:license sg:explorer/license/
41 sgo:sdDataset articles
42 rdf:type schema:ScholarlyArticle
43 N14d8f29074224c65879be7c7111aa7b1 schema:name pubmed_id
44 schema:value 30949758
45 rdf:type schema:PropertyValue
46 N17885ed1e35d431c8b551f2fe207e46e schema:name doi
47 schema:value 10.1007/s00280-019-03819-0
48 rdf:type schema:PropertyValue
49 N19c6380ccb354e989390a49266f1b2df schema:affiliation https://www.grid.ac/institutes/grid.411646.0
50 schema:familyName Sørensen
51 schema:givenName Peter Grundtvig
52 rdf:type schema:Person
53 N1b3e835043854e05ac90032b9e53304d rdf:first N19c6380ccb354e989390a49266f1b2df
54 rdf:rest N618a15cdc429494794ed39bdd0211bfa
55 N20789154b75a402b9b033447564c13ca rdf:first N81b011c96f484671952af671e71b4368
56 rdf:rest N86b6106da96c4868ba2df8c1daeb2562
57 N31a0cec6b7ca4c70bc69feabb2645a4e rdf:first Ndc14e29892384b429dfa381e2e977b94
58 rdf:rest rdf:nil
59 N33c97958cdcf480eaf07123cbf59cd68 rdf:first Ne8a275d526334032a61086b5d5e0848d
60 rdf:rest Na63e069895ae4277b63030083af1c5fa
61 N4f69ffcdc1f4460ab52d0020199cf8e0 schema:name Springer Nature - SN SciGraph project
62 rdf:type schema:Organization
63 N53f5b8c59f2d447eb989bb3a60b54bcb schema:name nlm_unique_id
64 schema:value 7806519
65 rdf:type schema:PropertyValue
66 N618a15cdc429494794ed39bdd0211bfa rdf:first N97ed06038b2d46e18a1cf3f0628bf7c7
67 rdf:rest N68ec1bfc71f142d7a95759cd9e683ff7
68 N68ec1bfc71f142d7a95759cd9e683ff7 rdf:first Nd6736a8c8a5647d583571bea994afa41
69 rdf:rest N20789154b75a402b9b033447564c13ca
70 N7c65f73f7bd74aae8a8214f4a31d2717 schema:name Oncoral Pharma ApS, c/o Jusmedico, Kongevejen 371, Holte, Denmark.
71 rdf:type schema:Organization
72 N81b011c96f484671952af671e71b4368 schema:affiliation Nb03cb6d5cbc54d6380248224bfe6686c
73 schema:familyName Nielsen
74 schema:givenName P G
75 rdf:type schema:Person
76 N86b6106da96c4868ba2df8c1daeb2562 rdf:first Nf2fc3a0af8224a9aa894ab12ec66f978
77 rdf:rest N31a0cec6b7ca4c70bc69feabb2645a4e
78 N97ed06038b2d46e18a1cf3f0628bf7c7 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
79 schema:familyName Theile
80 schema:givenName S
81 rdf:type schema:Person
82 Na63e069895ae4277b63030083af1c5fa rdf:first Nb584cd8897664b24bfed439a32092f01
83 rdf:rest N1b3e835043854e05ac90032b9e53304d
84 Nab6c406afe36432d8adb82751f970cbf schema:name dimensions_id
85 schema:value pub.1113185174
86 rdf:type schema:PropertyValue
87 Nb03cb6d5cbc54d6380248224bfe6686c schema:name Oncoral Pharma ApS, c/o Jusmedico, Kongevejen 371, Holte, Denmark.
88 rdf:type schema:Organization
89 Nb584cd8897664b24bfed439a32092f01 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
90 schema:familyName Eefsen
91 schema:givenName R L
92 rdf:type schema:Person
93 Nd6736a8c8a5647d583571bea994afa41 schema:affiliation N7c65f73f7bd74aae8a8214f4a31d2717
94 schema:familyName Fullerton
95 schema:givenName A
96 rdf:type schema:Person
97 Ndc14e29892384b429dfa381e2e977b94 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
98 schema:familyName Nielsen
99 schema:givenName D L
100 rdf:type schema:Person
101 Ne8a275d526334032a61086b5d5e0848d schema:affiliation https://www.grid.ac/institutes/grid.411646.0
102 schema:familyName Kümler
103 schema:givenName I
104 rdf:type schema:Person
105 Nf2fc3a0af8224a9aa894ab12ec66f978 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
106 schema:familyName Jensen
107 schema:givenName Benny Vittrup
108 rdf:type schema:Person
109 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
110 schema:name Medical and Health Sciences
111 rdf:type schema:DefinedTerm
112 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
113 schema:name Clinical Sciences
114 rdf:type schema:DefinedTerm
115 sg:journal.1088364 schema:issn 0344-5704
116 1432-0843
117 schema:name Cancer Chemotherapy and Pharmacology
118 rdf:type schema:Periodical
119 sg:pub.10.1007/s00280-004-0874-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007848801
120 https://doi.org/10.1007/s00280-004-0874-2
121 rdf:type schema:CreativeWork
122 sg:pub.10.1007/s00280-018-3720-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109785986
123 https://doi.org/10.1007/s00280-018-3720-7
124 rdf:type schema:CreativeWork
125 sg:pub.10.1007/s10637-010-9528-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1026463355
126 https://doi.org/10.1007/s10637-010-9528-x
127 rdf:type schema:CreativeWork
128 sg:pub.10.1007/s10637-012-9824-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010172644
129 https://doi.org/10.1007/s10637-012-9824-8
130 rdf:type schema:CreativeWork
131 sg:pub.10.1186/1471-2407-14-986 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015583184
132 https://doi.org/10.1186/1471-2407-14-986
133 rdf:type schema:CreativeWork
134 https://app.dimensions.ai/details/publication/pub.1077675908 schema:CreativeWork
135 https://doi.org/10.1016/s1470-2045(18)30140-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101553187
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1093/annonc/mdl071 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008381637
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1093/annonc/mds122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033567728
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1093/annonc/mdu260 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029291056
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1093/annonc/mdv295 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045601700
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1093/annonc/mdw350 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079330788
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1097/00000421-198212000-00014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045278392
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1097/coc.0b013e31804b40bb schema:sameAs https://app.dimensions.ai/details/publication/pub.1022936341
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1097/mcg.0b013e3182470f09 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037963679
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1158/1078-0432.ccr-05-2368 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024763018
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1177/1758834009355164 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064077267
156 rdf:type schema:CreativeWork
157 https://doi.org/10.4143/crt.2017.562 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101054104
158 rdf:type schema:CreativeWork
159 https://www.grid.ac/institutes/grid.411646.0 schema:alternateName Gentofte Hospital
160 schema:name Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark.
161 Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark. ibekml01@regionh.dk.
162 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...